Due to the evident implication of the IL6/JAK/STAT pathway in HNSCC progression and therapy resistance, the development of IL-6R-alpha (tocilizumab) and JAK1/2 inhibitors (AZD1480) is extremely promising for the treatment of both primary and cisplatin-refractory HNSCCs, although its clinical benefits remain to be proven. This evidence concerns the gene SOAT1 and head and neck squamous cell carcinoma.